Worldwide SARS-CoV-2 Omicron variant infection: Emerging sub-variants and future vaccination perspectives DOI Creative Commons

Yu-An Kung,

Chih-Hsien Chuang,

Yi-Ching Chen

et al.

Journal of the Formosan Medical Association, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 1, 2024

The coronavirus disease 2019 (COVID-19) pandemic has sparked widespread concern globally, particularly with the Omicron variant and its sub-lineages emerging as predominant cause of infection for nearly two years. Taiwan's successful containment COVID-19, underscored by broad vaccine coverage, utilization anti-viral therapeutics, timely response strategies, resulted in reduced excess mortality. Moreover, there is a crucial need phased exit strategy, balancing efforts to curtail transmission mitigation socioeconomic impacts from rigorous measures. In this review, we examined evolution epidemiological landscape severe acute respiratory syndrome 2 (SARS-CoV-2) sub-variants Taiwan well other countries world. We also critically evaluated effectiveness COVID-19 vaccines against various SARS-CoV-2 variants. Additionally, addressed advantages heterologous immunization fluctuations neutralizing antibody titers, complexities establishing protective correlates among swiftly mutating viral

Language: Английский

XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1 DOI Creative Commons
Qian Wang, Yicheng Guo, Anthony Bowen

et al.

Cell Host & Microbe, Journal Year: 2024, Volume and Issue: 32(3), P. 315 - 321.e3

Published: Feb. 19, 2024

COVID-19 vaccines have recently been updated to specifically encode or contain the spike protein of SARS-CoV-2 XBB.1.5 subvariant, but their immunogenicity in humans has yet be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding. We now report administration an monovalent mRNA vaccine booster (XBB.1.5 MV) previously uninfected individuals boosted serum virus-neutralizing antibodies significantly not only (27.0-fold increase) EG.5.1 (27.6-fold also key emerging such as HV.1, HK.3, JD.1.1, JN.1 (13.3- 27.4-fold increase). Individuals infected by Omicron subvariant had highest overall neutralizing titers (ID

Language: Английский

Citations

111
Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024 DOI Creative Commons
Anne J. Huiberts, Christina E. Hoeve, Brechje de Gier

et al.

Eurosurveillance, Journal Year: 2024, Volume and Issue: 29(10)

Published: March 7, 2024

We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and January 2024 in 23,895 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23–55) 18–59-year-olds 50% 44–56) 60–85-year-olds. Sequencing data suggest lower protection the BA.2.86 (including JN.1) variant from recent prior (OR = 2.8; 95% CI:1.2–6.5) and, not statistically significant, 1.5; CI:0.8–2.6).

Language: Английский

Citations

32
SARS-CoV-2 Variants: Genetic Insights, Epidemiological Tracking, and Implications for Vaccine Strategies DOI Open Access
Fatimah S. Alhamlan, Ahmed A. Al‐Qahtani

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(3), P. 1263 - 1263

Published: Jan. 31, 2025

The emergence of SARS-CoV-2 variants has significantly impacted the global response to COVID-19 pandemic. This review examines genetic diversity variants, their roles in epidemiological tracking, and influence on viral fitness. Variants concern (VOCs) such as Alpha, Beta, Gamma, Delta, Omicron have demonstrated increased transmissibility, altered pathogenicity, potential resistance neutralizing antibodies. Epidemiological tracking these is crucial for understanding spread, informing public health interventions, guiding vaccine development. also explores how specific mutations spike protein other genomic regions contribute fitness, affecting replication efficiency, immune escape, transmission dynamics. By integrating surveillance data with clinical findings, this provides a comprehensive overview ongoing evolution its implications strategies new

Language: Английский

Citations

1
Immunogen characterization reveals an intrinsic hindrance in eliciting neutralizing antibodies against JN.1 variant DOI Creative Commons

Junhao Fan,

Yao Zhang,

Shixiong Li

et al.

iScience, Journal Year: 2024, Volume and Issue: 27(8), P. 110405 - 110405

Published: June 28, 2024

Language: Английский

Citations

1
Worldwide SARS-CoV-2 Omicron variant infection: Emerging sub-variants and future vaccination perspectives DOI Creative Commons

Yu-An Kung,

Chih-Hsien Chuang,

Yi-Ching Chen

et al.

Journal of the Formosan Medical Association, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 1, 2024

The coronavirus disease 2019 (COVID-19) pandemic has sparked widespread concern globally, particularly with the Omicron variant and its sub-lineages emerging as predominant cause of infection for nearly two years. Taiwan's successful containment COVID-19, underscored by broad vaccine coverage, utilization anti-viral therapeutics, timely response strategies, resulted in reduced excess mortality. Moreover, there is a crucial need phased exit strategy, balancing efforts to curtail transmission mitigation socioeconomic impacts from rigorous measures. In this review, we examined evolution epidemiological landscape severe acute respiratory syndrome 2 (SARS-CoV-2) sub-variants Taiwan well other countries world. We also critically evaluated effectiveness COVID-19 vaccines against various SARS-CoV-2 variants. Additionally, addressed advantages heterologous immunization fluctuations neutralizing antibody titers, complexities establishing protective correlates among swiftly mutating viral

Language: Английский

Citations

1